Transgenomic Licenses Exclusive Rights to Cold PCR | GenomeWeb

NEW YORK (GenomeWeb News) – Transgenomic has licensed exclusive rights to Cold-PCR technology from the Dana Farber Cancer Institute, the firm said Thursday.

The Omaha, Neb.-based pharmacogenomics firm said that it has exclusive rights to commercialize the technology for combined use with Sanger sequencing as well as for mitochondrial DNA analysis. Financial and further terms of the license were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.